



IFC/ /
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Veldhuis et al.

Serial No.: 10/676,847

Filed: October 1, 2003

For: METHOD OF TREATMENT OF
HYPOXIA/ISCHAEMIA

Confirmation No.: 3770

Examiner: J. Galvez

Group Art Unit: 1647

Attorney Docket No.: 2183-6139US

CERTIFICATE OF MAILING

I hereby certify that this correspondence along with any attachments referred to or identified as being attached or enclosed is being deposited with the United States Postal Service as First Class Mail on the date of deposit shown below with sufficient postage and in an envelope addressed to the Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

October 12, 2005
Date


Signature

Betty Vowles
Name (Type/Print)

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In compliance with the duty to disclose information material to patentability pursuant to 37 C.F.R. § 1.56, it is respectfully requested that this Supplemental Information Disclosure Statement be entered and the documents listed on attached Form PTO/SB/08 be considered by the Examiner and made of record. Copies of the listed documents are enclosed pursuant to 37 C.F.R. § 1.98(a).

10/17/2005 YPOLITE1 00000035 10676847

01 FC:1806

180.00 OP

Other Documents

DEFAZIO et al., "ICAM expression and fluid phase endocytosis of cultured brain microvascular endothelial cells following exposure to interferon Beta-1a and TNF-Alpha," *Journal of Neuroimmunology*, 1998, pp. 13-20, vol. 88.

DHIB-JALBUT et al., "The effect of interferon Beta-1b on lymphocyte-endothelial cell adhesion," *Journal of Neuroimmunology*, 1996, pp. 215-222, vol. 71.

DOMANSKI et al., "Cloning and Expression of a Long Form of the Beta Subunit of the Interferon Alpha Beta Receptor That Is Required for Signaling," *The Journal of Biological Chemistry*, 15 September 1995, pp. 21606-21611, vol. 270, no. 37.

EMMETT et al., "Evaluation of Human Astrocytoma and Glioblastoma Cell Lines for Nerve Growth Factor Release," *Neurochem. Int.*, 1997, pp. 465-474, vol. 30, nos. 4/5.

THE ENLIMOMAB ACUTE STROKE TRIAL INVESTIGATORS, "The Enlimomab Acute Stroke Trial: Final Results," *Neurology*, March 1997, pp. A270, vol. 48.

THE ENLIMOMAB ACUTE STROKE TRAL INVESTIGATORS, "Use of anti-ICAM-1 therapy in ischemic stroke: Results of the Enlimomab Acute Stroke Trial," *Neurology*, October 2001, pp. 1428-1434, vol. 57.

GARLANDA et al., "Heterogeneity of Endothelial Cells: Specific Markers," *Arteriosclerosis, Thrombosis, and Vascular Biology*, 1997, pp. 1193-1202, vol. 17.

KASTE et al., "Combined dexamethasone and low-molecular-weight dextran in acute brain infarction: double blind study," *Br Med J.*, 11 December 1976, pp. 1409-1410, vol. 2, no. 6049. Abstract.

KRAMS et al., "Acute Stroke Therapy by Inhibition of Neutrophils (ASTIMS): An Adaptive Dose-Response Study of UK-279,276 in Acute Ischemic Stroke," *Stroke*, pp. 2543-2548, November 2003.

MULLEY et al., "Dexamethasone in acute stroke," *Br Med J.*, 7 October 1978, pp. 994-996, vol. 2, no. 6143. Abstract.

NORRIS et al., "High dose steroid treatment in cerebral infarction," *Br Med J (Clin Res Ed.)*, 4 January 1986, pp. 21-23, vol. 292, no. 6512. Abstract.

NOVICK et al., "The Human Interferon Alpha/Beta receptor: Characterization and molecular Cloning," *Cell*, 6 May 1994, pp. 391-400, vol. 77.

QIZILBASH et al., "Corticosteroids for acute ischaemic stroke," *The Cochrane Database of Systematic reviews*, 2005, vol. 3. Abstract.

SOILU-HANNINEN et al., "Interferon-Beta down regulates expression of VLA-4 antigen and antagonizes interferon- γ -induced expression of HLA-DQ on human peripheral blood monocytes," *Journal of Neuroimmunology*, 1995, pp. 99-106, vol. 60.

TROJANO et al., "Effects of r IFN-Beta-1b on Serum circulating ICAM-1 in relapsing remitting multiple sclerosis and on the membrane-bound ICAM-1 expression on brain microvascular endothelial cells," *Journal of NeuroVirology*, 2000, pp. S47-S51, vol. 6.

This Supplemental Information Disclosure Statement is filed after the mailing date of the first Office Action on the merits.

The fee pursuant to 37 C.F.R. § 1.17(p) is enclosed.

Respectfully submitted,



Kelly A. Echols
Registration No. 55,911
Attorney for Applicant(s)
TRASKBRITT, P.C.
P.O. Box 2550
Salt Lake City, Utah 84110-2550
Telephone: 801-532-1922

Date: October 11, 2005
KAE/alb

Enclosures: Form PTO/SB/08
Copy of documents cited
Check in the amount of \$180.00

Document in ProLaw



PTO/SB/08B(10-03)

Approved for use through 7/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

1 of 2

Complete if Known

Application Number	10/676,847
Filing Date	October 1, 2003
First Named Inventor	Veldhuis et al.
Group Art Unit	1647
Examiner Name	J. Galvez
Attorney Docket Number	2183-613911S

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		DEFAZIO et al., "ICAM expression and fluid phase endocytosis of cultured brain microvascular endothelial cells following exposure to interferon Beta-1a and TNF-Alpha," <i>Journal of Neuroimmunology</i> , 1998, pp. 13-20, vol. 88.	
		DHIB-JALBUT et al., "The effect of interferon Beta-1b on lymphocyte-endothelial cell adhesion," <i>Journal of Neuroimmunology</i> , 1996, pp. 215-222, vol. 71.	
		DOMANSKI et al., "Cloning and Expression of a Long Form of the Beta Subunit of the Interferon Alpha Beta Receptor That Is Required for Signaling," <i>The Journal of Biological Chemistry</i> , 15 September 1995, pp. 21606-21611, vol. 270, no. 37.	
		EMMETT et al., "Evaluation of Human Astrocytoma and Glioblastoma Cell Lines for Nerve Growth Factor Release," <i>Neurochem. Int.</i> , 1997, pp. 465-474, vol. 30, nos. 4/5.	
		THE ENLIMOMAB ACUTE STROKE TRIAL INVESTIGATORS, "The Enlimomab Acute Stroke Trial: Final Results," <i>Neurology</i> , March 1997, pp. A270, vol. 48.	
		THE ENLIMOMAB ACUTE STROKE TRAL INVESTIGATORS, "Use of anti-ICAM-1 therapy in ischemic stroke: Results of the Enlimomab Acute Stroke Trial," <i>Neurology</i> , October 2001, pp. 1428-1434, vol. 57.	
		GARLANDA et al., "Heterogeneity of Endothelial Cells: Specific Markers," <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1997, pp. 1193-1202, vol. 17.	
		KASTE et al., "Combined dexamethasone and low-molecular-weight dextran in acute brain infarction: double blind study," <i>Br Med J.</i> , 11 December 1976, pp. 1409-1410, vol. 2, no. 6049. Abstract.	
		KRAMS et al., "Acute Stroke Therapy by Inhibition of Neutrophils (ASTIMS): An Adaptive Dose-Response Study of UK-279,276 in Acute Ischemic Stroke," <i>Stroke</i> , pp. 2543-2548, November 2003.	
		MULLEY et al., "Dexamethasone in acute stroke," <i>Br Med J.</i> , 7 October 1978, pp. 994-996, vol. 2, no. 6143. Abstract.	
		NORRIS et al., "High dose steroid treatment in cerebral infarction," <i>Br Med J (Clin Res Ed.)</i> , 4 January 1986, pp. 21-23, vol. 292, no. 6512. Abstract.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

2

of

2

Complete if Known

Application Number	10/676,847
Filing Date	October 1, 2003
First Named Inventor	Veldhuis et al.
Group Art Unit	1647
Examiner Name	J. Galvez
Attorney Docket Number	2183-6139IJS

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		NOVICK et al., "The Human Interferon Alpha/Beta receptor: Characterization and molecular Cloning," Cell, 6 May 1994, pp. 391-400, vol. 77.	
		QIZILBASH et al., "Corticosteroids for acute ischaemic stroke," The Cochrane Database of Systematic reviews, 2005, vol. 3. Abstract.	
		SOILU-HANNINEN et al., "Interferon-Beta down regulates expression of VLA-4 antigen and antagonizes interferon- γ -induced expression of HLA-DQ on human peripheral blood monocytes," Journal of Neuroimmunology, 1995, pp. 99-106, vol. 60.	
		TROJANO et al., "Effects of r IFN-Beta-1b on Serum circulating ICAM-1 in relapsing remitting multiple sclerosis and on the membrane-bound ICAM-1 expression on brain microvascular endothelial cells," Journal of NeuroVirology, 2000, pp. S47-S51, vol. 6.	
		UZE et al., "Genetic Transfer of a Functional Human Interferon Alpha Receptor into Mouse Cells: Cloning and Expression of Its cDNA," Cell, 26 January 1990, pp. 225-234, vol. 60.	

Examiner
SignatureDate
Considered

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

²Unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.